PPA
CRVS icon

Parametric Portfolio Associates’s Corvus Pharmaceuticals CRVS Stock Holding History

Parametric Portfolio Associates’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,359
Closed -$50K – 3947
2019
Q2 		$50K Buy
+13,359
New +$52.3K ﹤0.01% 3909

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parametric Portfolio Associates's CRVS Position: Q3 2019 in Review

Parametric Portfolio Associates sold out of Corvus Pharmaceuticals (CRVS) in Q3 2019, closing a stake of 13,359 shares — an estimated $50K sold.

Parametric Portfolio Associates first reported a position in CRVS in Q2 2019 and held it in 1 quarter. The position peaked at $50K in Q2 2019. 35 funds tracked by Wall St. Rank hold CRVS as of Q3 2019.

  • Parametric Portfolio Associates reported no remaining Corvus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Parametric Portfolio Associates sold 13,359 Corvus Pharmaceuticals shares in Q3 2019, an estimated $50K.
  • Parametric Portfolio Associates first reported a position in Corvus Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Parametric Portfolio Associates's Corvus Pharmaceuticals position peaked at $50K in Q2 2019.
  • 35 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2019.

Based on Parametric Portfolio Associates's 13F filing for Q3 2019, filed 15 Nov 2019.